Allogene Therapeutics (ALLO) Equity Average (2019 - 2025)
Historic Equity Average for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $329.9 million.
- Allogene Therapeutics' Equity Average fell 3258.08% to $329.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.9 million, marking a year-over-year decrease of 3258.08%. This contributed to the annual value of $467.2 million for FY2024, which is 2075.31% down from last year.
- Allogene Therapeutics' Equity Average amounted to $329.9 million in Q3 2025, which was down 3258.08% from $365.0 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Equity Average peaked at $1.1 billion during Q1 2021, and registered a low of $329.9 million during Q3 2025.
- Its 5-year average for Equity Average is $666.7 million, with a median of $606.7 million in 2023.
- As far as peak fluctuations go, Allogene Therapeutics' Equity Average skyrocketed by 7396.38% in 2021, and later plummeted by 3258.08% in 2025.
- Allogene Therapeutics' Equity Average (Quarter) stood at $947.6 million in 2021, then fell by 25.58% to $705.1 million in 2022, then fell by 22.51% to $546.4 million in 2023, then fell by 18.94% to $443.0 million in 2024, then dropped by 25.51% to $329.9 million in 2025.
- Its last three reported values are $329.9 million in Q3 2025, $365.0 million for Q2 2025, and $403.8 million during Q1 2025.